Lannett (NYSE:LCI) gains 7.1% in premarket trading after the FDA approves ANDAs for two dosage strengths of butalbital, acetaminophen, and caffeine capsules.
The company has started marketing BAC capsules, USP, 50mg/300mg/40mg and BAC capsules, USP, 50 mg/325mg/40mg.
The two dosage strengths have a combined estimated IQVIA market value of ~$68.6M for the 12 months ending October 2019, although actual generic market values are expected to be lower.
LCI sees launching as many as 12 products in the next six months.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.